# Bemdec Prescribing Guide

> Bedside prescribing reference for Bemdec (bempedoic acid / NEXLETOL) — indication check, dose, statin co-prescribing safety caps, monitoring plan, warnings for hyperuricemia and tendon rupture, and special population guidance. Use when a clinician asks "can I start bempedoic acid", "Bemdec indication", "is bempedoic acid safe with my statin", "patient on Nexletol has joint pain or high uric acid", "bempedoic acid in CKD or liver disease or pregnancy", or any prescribing or monitoring question about bempedoic acid.

- Skill: `dromlakhani/bemdec-prescribing-guide` (Agent Skill)
- Install (CLI): `npx skillmds add dromlakhani/bemdec-prescribing-guide`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/bemdec-prescribing-guide/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-08-19
- Page: https://skillmd.com/skills/dromlakhani/bemdec-prescribing-guide

---


# Bemdec (Bempedoic Acid) — Prescribing Guide

**Brand:** Bemdec (India) | NEXLETOL (USA)  
**Class:** ATP-citrate lyase (ACL) inhibitor — reduces hepatic cholesterol synthesis upstream of HMG-CoA reductase  
**Dose:** 180 mg orally once daily, with or without food

---

## Step 1 — Confirm the Indication

Bempedoic acid is indicated as **add-on to maximally tolerated statin therapy** in adults who need further LDL-C lowering with either:

- **Heterozygous familial hypercholesterolaemia (HeFH)**, OR
- **Established atherosclerotic cardiovascular disease (ASCVD)**

> ⚠️ CV morbidity/mortality benefit has **not** been established. It lowers LDL-C, not proven outcomes (as of 2020 label).  
> Not approved in children (<18 years).

---

## Step 2 — Check the Current Statin for Interaction

This is the most important safety check before prescribing.

| Statin | Action Required |
|--------|----------------|
| Simvastatin **>20 mg/day** | **Reduce to ≤20 mg** or switch statin before starting Bemdec |
| Pravastatin **>40 mg/day** | **Reduce to ≤40 mg** or switch statin before starting Bemdec |
| Atorvastatin | No dose cap — safe at any approved dose |
| Rosuvastatin | No dose cap — safe at any approved dose |

**Why:** Bemdec raises simvastatin AUC ~2-fold and pravastatin AUC ~2-fold → increased myopathy risk. Atorvastatin and rosuvastatin elevations are minor (~1.7-fold) and do not require dose adjustment.

---

## Step 3 — Screen Special Populations Before Starting

| Population | Decision |
|------------|----------|
| Pregnancy | **Stop Bemdec** unless benefit clearly outweighs fetal risk. Advise contraception. |
| Breastfeeding | **Avoid** — potential harm to infant; mechanism-based concern |
| Renal: mild–moderate (eGFR ≥30) | **No dose adjustment needed** |
| Renal: severe (eGFR <30) / ESRD on dialysis | **Limited data — use with caution; not studied in ESRD** |
| Hepatic: Child-Pugh A or B | **No dose adjustment needed** |
| Hepatic: Child-Pugh C | **Not studied — avoid** |
| Age ≥65 | **No dose adjustment** — well-represented in trials (58% were ≥65) |
| Prior gout history | ⚠️ **High risk for gout flare** — check uric acid before starting; consider prophylaxis |
| Prior tendon disorders | ⚠️ **Higher tendon rupture risk** — discuss alternative therapy |

---

## Step 4 — Start and Schedule Monitoring

1. **Start:** 180 mg once daily with maximally tolerated statin
2. **Lipid check:** Recheck LDL-C at **8–12 weeks** after initiation
3. **Uric acid:** Check at baseline and at **4 weeks** (peak rise occurs in first 4 weeks)
4. **LFTs / CK:** Check if symptoms develop — not required routinely unless symptomatic

---

## Step 5 — Monitor and Manage Adverse Effects

### 🔴 Hyperuricemia (Gout Risk)
- **Incidence:** Uric acid rises in 26% of patients; clinically significant hyperuricemia in 3.5%
- **Gout:** 1.5% on Bemdec vs 0.4% placebo; rises to **11.2% in those with prior gout history**
- **Action:** 
  - Asymptomatic rise: monitor periodically
  - Symptomatic gout: start urate-lowering therapy (allopurinol/febuxostat); do not stop Bemdec unless severe

### 🔴 Tendon Rupture
- **Incidence:** 0.5% vs 0% placebo — rotator cuff, biceps, Achilles most common
- **Risk factors:** Age >60, corticosteroids, fluoroquinolones, renal failure, prior tendon disorder
- **Red flags — STOP IMMEDIATELY:** snap/pop sensation, acute pain, bruising over tendon, inability to move/weight-bear
- **Yellow flags — consider stopping:** new joint pain, swelling, or inflammation → switch to alternative lipid-lowering therapy
- **Rule:** Discontinue Bemdec at first sign of tendon rupture. Avoid in patients with prior tendon rupture history.

### Common Adverse Effects (≥2%, >placebo)

| Effect | Bemdec | Placebo |
|--------|--------|---------|
| Muscle spasms | 3.6% | 2.3% |
| Hyperuricemia | 3.5% | 1.1% |
| Back pain | 3.3% | 2.2% |
| Abdominal pain | 3.1% | 2.2% |
| Pain in extremity | 3.0% | 1.7% |
| Elevated liver enzymes | 2.1% | 0.8% |

> AST elevations >3× ULN: 1.4% vs 0.4%. Usually transient. Check LFTs if symptomatic.  
> Haemoglobin drop ≥2 g/dL: 5.1% — generally asymptomatic.  
> Platelet rise >100×10⁹/L: 10.1% — not clinically significant.

---

## Step 6 — Patient Counselling Points

1. Take once daily, with or without food
2. Inform about gout risk — report severe joint pain, swelling especially in the big toe
3. Inform about tendon risk — rest immediately and call if snap/pop/pain in shoulder, upper arm, or heel
4. Alert on simvastatin/pravastatin muscle risk if co-prescribed
5. Stop and call if pregnant
6. LDL-C check at 8–12 weeks after starting

---

## Clinical Guardrails

- **Do not use** as monotherapy — must be adjunct to maximally tolerated statin
- **Do not combine** with simvastatin >20 mg or pravastatin >40 mg
- **Do not start** in Child-Pugh C or ESRD — no safety data
- **Do not ignore** new musculoskeletal complaints — could be tendon warning
- Bempedoic acid does **not** interact with warfarin, metformin, or oral contraceptives

---

**Source:** NEXLETOL (bempedoic acid) FDA Prescribing Information. Esperion Therapeutics, Inc. Reference ID: 4564667. Revised: 02/2020. https://www.fda.gov/drugsatfda